相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies
Mohammed Dagher et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial
Gonzalo Tapia Rico et al.
CLINICAL COLORECTAL CANCER (2019)
Integrated safety summary for trifluridine/tipiracil (TAS-102)
Alfredo Falcone et al.
ANTI-CANCER DRUGS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara et al.
LANCET ONCOLOGY (2018)
Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients
Masatsune Shibutani et al.
CASE REPORTS IN ONCOLOGY (2018)
O-012Prognosis of lung metastases in patients with metastatic colorectal cancer: an ARCAD meta analysis
J. Henriques et al.
ANNALS OF ONCOLOGY (2017)
Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy
Gemma Bruera et al.
ONCOTARGET (2017)
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
Yasutoshi Kuboki et al.
LANCET ONCOLOGY (2017)
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Carmine Pinto et al.
CLINICAL COLORECTAL CANCER (2017)
Colorectal cancer statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
A novel antimetabolite: TAS-102 for metastatic colorectal cancer
Yuji Miyamoto et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example
Stine Braendegaard Winther et al.
ESMO OPEN (2016)
TAS-102, a novel antitumor agent: A review of the mechanism of action
Heinz-Josef Lenz et al.
CANCER TREATMENT REVIEWS (2015)
Metastatic Colorectal Cancer: Current State and Future Directions
Marwan G. Fakih
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
How to select the optimal treatment for first line metastatic colorectal cancer
Alexander Stein et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
David Cunningham et al.
LANCET ONCOLOGY (2013)
Screening older cancer patients: first evaluation of the G-8 geriatric screening tool
C. A. Bellera et al.
ANNALS OF ONCOLOGY (2012)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino et al.
LANCET ONCOLOGY (2012)
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
M. Herdman et al.
QUALITY OF LIFE RESEARCH (2011)
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Niall C. Tebbutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
分享论文
